🧬 This Week in Immunology: European Access Gaps, PsA Milestones, and Needle-Free Epinephrine
Stay up to date with the latest developments in immunology—spanning health system disparities, long-term biologic data, digital health tools, and first-in-class autoimmune therapies:
🌍 EULAR RheumaFacts reveals European care gaps
💊 Dapirolizumab Pegol improves lupus outcomes
💥 Pozdeutinurad shows sustained benefit in chronic gout
🧴 Bimzelx and Sotyktu show durable efficacy in psoriatic arthritis
🛡 Guselkumab becomes the first IL-23 inhibitor to reduce structural joint damage in PsA at Week 24
📱 GHLF launches arthritis-focused digital tools
🧪 SciBase and Castle team up on AD flare prediction
🧔🏽 Dupilumab benefits patients of color with AD
✨ Nemolizumab approved for NHS use
🧬 ZL-1503 bispecific antibody delivers durable preclinical results
🌬 Rademikibart reduces asthma exacerbations by up to 74%
🔬 IW-601 shows early safety and target engagement in Phase 1
💊 Anaphylm™ oral epinephrine tablet gets FDA review date
📢 Stay Ahead in Immunology Research!
✅ Like, share, and subscribe for weekly updates on the latest in immunology and autoimmune diseases
#Immunology #Lupus #ChronicGout #PsoriaticArthritis #HealthEquity #AutoimmuneResearch #Biologics #AtopicDermatitis #AsthmaCare #Anaphylaxis #DigitalHealth #ClinicalTrials #LucidQuest #ImmunologyUpdates